Canichella Martina, de Fabritiis Paolo
Hematology Unit, St. Eugenio Hospital, ASL Roma2, 00144 Rome, Italy.
Department of Biomedicine and Prevention, Tor Vergata University, 00133 Rome, Italy.
Biomedicines. 2024 Aug 1;12(8):1721. doi: 10.3390/biomedicines12081721.
Allogeneic stem cell transplant (ASCT) remains the only treatment option for patients with high-risk acute myeloid leukemia (AML). Recurrence of leukemic cells after ASCT represents a dramatic event associated with a dismal outcome, with a 2-year survival rate of around 20%. Adoptive cell therapy (ACT) is a form of cell-based strategy that has emerged as an effective therapy to treat and prevent post-ASCT recurrence. Lymphocytes are the principal cells used in this therapy and can be derived from a hematopoietic stem cell donor, the patient themselves, or healthy donors, after being engineered to express the chimeric antigen receptor (CAR-T and UniCAR-T). In this review, we discuss recent advances in the established strategy of donor lymphocyte infusion (DLI) and the progress and challenges of CAR-T cells.
异基因干细胞移植（ASCT）仍然是高危急性髓系白血病（AML）患者的唯一治疗选择。ASCT后白血病细胞复发是一个与预后不良相关的重大事件，2年生存率约为20%。过继性细胞疗法（ACT）是一种基于细胞的策略，已成为治疗和预防ASCT后复发的有效疗法。淋巴细胞是该疗法中使用的主要细胞，可以来自造血干细胞供体、患者自身或健康供体，经过工程改造以表达嵌合抗原受体（CAR-T和UniCAR-T）。在本综述中，我们讨论了已确立的供体淋巴细胞输注（DLI）策略的最新进展以及CAR-T细胞的进展和挑战。
